Chenxiang Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chenxiang Cao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Wenhui Zhao
Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China
3 shared publications - Xiaoyi Wang
Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China
3 shared publications - Xuesong Li
School of Clinical Medicine Tsinghua University Beijing China
3 shared publications - Hongyu Li
Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China
2 shared publications Jianzhong Xiao
Department of Endocrine and Metabolism Beijing Tsinghua Changgung Hospital Beijing China
2 shared publications- Jianzhong Xiao
Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
2 shared publications
Latest Publications
- Open Access
Multi-Omic Mendelian Randomization Prioritizes Immune Regulatory Genes and Their Cell-Type-Resolved Effects Underlying Graves’ Disease Susceptibility
Background/Objectives: Graves’ disease (GD) susceptibility loci are well established, but the regulatory genes and immune cell types through which they act remain unclear. Methods: We integrated FinnGen R12 GD summary statistics (3962 cases) with GTEx v10 thyroid and whole-blood cis-eQTLs using SMR, HEIDI testing and colocalization, and narrowed candidates by eQTLGen transcript-level Mendelian randomization (MR). The resulting 14 core genes were tested against FinnGen GD, UK Biobank GD, the White et al. GD meta-analysis (12,019 cases) and FinnGen Graves’ ophthalmopathy (GO) at the transcript, plasma-protein (Olink, SomaScan) and single-cell (OneK1K, 14 immune cell types) levels, using LD-aware MR and complete-region colocalization with SuSiE fine-mapping. Results: Twelve core genes were supported under FDR control in the White et al. consolidation analysis, which includes FinnGen and UK Biobank. FCRL3 was the most consistently supported gene, with risk-direction associations colocalizing with GD in thyroid, blood, plasma and lymphocyte subsets. CD40 colocalized for thyroid expression and plasma protein but not for its monocyte eQTL. MMEL1 and UBASH3A had comparable support, colocalizing in blood and T-cell subsets; ACAP1 and the 11p11 locus provided supporting evidence. The RNASET2 protein association reflected a distinct pQTL variant. No GD–GO difference survived FDR correction. Conclusions: These results provide cell-type-annotated hypotheses for validation.
Open AccessMulti-Omic Mendelian Randomization Prioritizes Immune Regulatory Genes and Their Cell-Type-Resolved Effects Underlying Graves’ Disease Susceptibility
Background/Objectives: Graves’ disease (GD) susceptibility loci are well established, but the regulatory genes and immune cell types through which they act remain unclear. Methods: We integrated FinnGen R12 GD summary statistics (3962 cases) with GTEx v10 thyroid and whole-blood cis-eQTLs using SMR, HEIDI testing and colocalization, and narrowed candidates by eQTLGen transcript-level Mendelian randomization (MR). The resulting 14 core genes were tested against FinnGen GD, UK Biobank GD, the White et al. GD meta-analysis (12,019 cases) and FinnGen Graves’ ophthalmopathy (GO) at the transcript, plasma-protein (Olink, SomaScan) and single-cell (OneK1K, 14 immune cell types) levels, using LD-aware MR and complete-region colocalization with SuSiE fine-mapping. Results: Twelve core genes were supported under FDR control in the White et al. consolidation analysis, which includes FinnGen and UK Biobank. FCRL3 was the most consistently supported gene, with risk-direction associations colocalizing with GD in thyroid, blood, plasma and lymphocyte subsets. CD40 colocalized for thyroid expression and plasma protein but not for its monocyte eQTL. MMEL1 and UBASH3A had comparable support, colocalizing in blood and T-cell subsets; ACAP1 and the 11p11 locus provided supporting evidence. The RNASET2 protein association reflected a distinct pQTL variant. No GD–GO difference survived FDR correction. Conclusions: These results provide cell-type-annotated hypotheses for validation.
- Open Access
Cardiometabolic Composite Indices for Cardiovascular Risk Assessment in Diabetes: Information Overlap, Incremental Value, and Residual Risk Enrichment
Although cardiometabolic composite indices have shown associations with cardiovascular disease (CVD), it remains unclear whether they offer consistent risk information beyond that captured by established clinical predictors and their constituent variables. We aimed to determine whether 12 cardiometabolic composite indices provide cardiovascular risk information beyond conventional clinical factors and their individual components in adults with diabetes. The primary analyses included 1290 CHARLS participants with diabetes and no CVD at baseline, who were separated into development and fixed test sets; the principal findings were subsequently examined in an independent sample of 495 ELSA participants. Associations with incident CVD, information overlap, selection stability, model contribution, and incremental predictive performance were systematically assessed, followed by exploratory risk-stratified analyses. Estimated glucose disposal rate (eGDR) showed the most consistent risk signal. In CHARLS, each 1-standard-deviation increase in eGDR was associated with lower incident CVD risk (HR 0.65, 95% CI 0.56–0.75). Adding eGDR produced numerical increases in the C-index from 0.619 to 0.645 and the 9-year time-dependent AUC from 0.634 to 0.664, but paired bootstrap confidence intervals for these differences included zero, and eGDR did not clearly outperform its component variables. Among participants not classified as high risk, those with low eGDR comprised 36.4% of participants but accounted for 50.0% of subsequent CVD events; event proportions were 36.0% versus 20.6% (HR 1.84, 95% CI 1.12–3.04). In ELSA, higher eGDR was also associated with lower overall CVD risk, and similar numerical patterns in discrimination and residual-risk enrichment were observed, although the stroke-specific association was less clear. Overall, eGDR showed limited incremental discrimination, while exploratory risk-stratified analyses suggested possible residual-risk enrichment among participants with low eGDR; this finding requires prospective validation using prespecified thresholds.
Open AccessCardiometabolic Composite Indices for Cardiovascular Risk Assessment in Diabetes: Information Overlap, Incremental Value, and Residual Risk Enrichment
Although cardiometabolic composite indices have shown associations with cardiovascular disease (CVD), it remains unclear whether they offer consistent risk information beyond that captured by established clinical predictors and their constituent variables. We aimed to determine whether 12 cardiometabolic composite indices provide cardiovascular risk information beyond conventional clinical factors and their individual components in adults with diabetes. The primary analyses included 1290 CHARLS participants with diabetes and no CVD at baseline, who were separated into development and fixed test sets; the principal findings were subsequently examined in an independent sample of 495 ELSA participants. Associations with incident CVD, information overlap, selection stability, model contribution, and incremental predictive performance were systematically assessed, followed by exploratory risk-stratified analyses. Estimated glucose disposal rate (eGDR) showed the most consistent risk signal. In CHARLS, each 1-standard-deviation increase in eGDR was associated with lower incident CVD risk (HR 0.65, 95% CI 0.56–0.75). Adding eGDR produced numerical increases in the C-index from 0.619 to 0.645 and the 9-year time-dependent AUC from 0.634 to 0.664, but paired bootstrap confidence intervals for these differences included zero, and eGDR did not clearly outperform its component variables. Among participants not classified as high risk, those with low eGDR comprised 36.4% of participants but accounted for 50.0% of subsequent CVD events; event proportions were 36.0% versus 20.6% (HR 1.84, 95% CI 1.12–3.04). In ELSA, higher eGDR was also associated with lower overall CVD risk, and similar numerical patterns in discrimination and residual-risk enrichment were observed, although the stroke-specific association was less clear. Overall, eGDR showed limited incremental discrimination, while exploratory risk-stratified analyses suggested possible residual-risk enrichment among participants with low eGDR; this finding requires prospective validation using prespecified thresholds.
- Open Access
- 5 June 2026
- Published by MDPI AG in Geriatrics
- Vol. 11 (3) , 68
Visual Hallucinations and Cognitive Impairment as the Initial Presentation of Severe Hypothyroidism in an Elderly Patient: A Case Report
Background: Hypothyroidism is a prevalent endocrine disorder capable of affecting multiple organ systems. While somatic symptoms are common, prominent neuropsychiatric manifestations such as visual hallucinations and cognitive deficits are exceptionally rare as an initial presentation. This atypical clinical picture frequently leads to misdiagnosis as primary psychiatric disorders or neurodegenerative conditions. Case Presentation: We report the case of a 75-year-old male who presented with a three-month history of complex visual hallucinations and progressive cognitive decline. The hallucinations were notably dependent on environmental light. Initial assessments raised concerns about the neurodegenerative process. However, laboratory investigations revealed severe autoimmune hypothyroidism with high titers of anti-thyroid antibodies. Following timely levothyroxine replacement therapy, the patient achieved complete remission of visual hallucinations and significant cognitive recovery. Conclusions: This case illustrates that severe hypothyroidism can manifest as a reversible metabolic encephalopathy mimicking dementia. It underscores the importance of screening for thyroid dysfunction in elderly patients presenting with unexplained acute neuropsychiatric symptoms to ensure appropriate management.
- 5 June 2026
- Published by MDPI AG in Geriatrics
- Vol. 11 (3) , 68
Open AccessVisual Hallucinations and Cognitive Impairment as the Initial Presentation of Severe Hypothyroidism in an Elderly Patient: A Case Report
Background: Hypothyroidism is a prevalent endocrine disorder capable of affecting multiple organ systems. While somatic symptoms are common, prominent neuropsychiatric manifestations such as visual hallucinations and cognitive deficits are exceptionally rare as an initial presentation. This atypical clinical picture frequently leads to misdiagnosis as primary psychiatric disorders or neurodegenerative conditions. Case Presentation: We report the case of a 75-year-old male who presented with a three-month history of complex visual hallucinations and progressive cognitive decline. The hallucinations were notably dependent on environmental light. Initial assessments raised concerns about the neurodegenerative process. However, laboratory investigations revealed severe autoimmune hypothyroidism with high titers of anti-thyroid antibodies. Following timely levothyroxine replacement therapy, the patient achieved complete remission of visual hallucinations and significant cognitive recovery. Conclusions: This case illustrates that severe hypothyroidism can manifest as a reversible metabolic encephalopathy mimicking dementia. It underscores the importance of screening for thyroid dysfunction in elderly patients presenting with unexplained acute neuropsychiatric symptoms to ensure appropriate management.
- Open Access
- 9 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (32) , e39190
Levothyroxine sodium tablets reversed Hashimoto thyroiditis-induced kidney injury, muscle injury, and lipid metabolism disorder: A case report and literature review
Rationale: Hashimoto thyroiditis (HT), a common cause of hypothyroidism, has shown an increasing incidence in recent years, particularly among women. In addition to the common complications such as lipid metabolism disorders, patients with HT may also experience some serious complications, acute kidney injury and severe muscle damage for instance. This article explored the effectiveness of levothyroxine sodium tablets (L-T4) replacement therapy in severe complications of hypothyroidism, including treatment dosage, duration of complication recovery, and whether additional treatment is needed. Patient concerns, Diagnoses, and Interventions: We described a case of a 52-year-old woman with HT who exhibited kidney injury, muscle injury, and lipid metabolism disorders. The increased levels of serum creatinine, creatine kinase, cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and the decreased levels of estimated glomerular filtration rate were obviously observed. This patient was started on L-T4 (75 and 100 µg, alternate). Outcomes and Lessons: Following a two-month treatment, the serum creatine kinase level decreased to within normal range. The estimated glomerular filtration rate level was restored, and the serum creatinine level was down-regulated, although slightly higher than the normal range. L-T4 partially reversed HT-induced the disorders of muscle, renal function, and lipid profile of this patient and remarkably alleviated her HT-related symptoms.
- 9 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (32) , e39190
Open AccessLevothyroxine sodium tablets reversed Hashimoto thyroiditis-induced kidney injury, muscle injury, and lipid metabolism disorder: A case report and literature review
Rationale: Hashimoto thyroiditis (HT), a common cause of hypothyroidism, has shown an increasing incidence in recent years, particularly among women. In addition to the common complications such as lipid metabolism disorders, patients with HT may also experience some serious complications, acute kidney injury and severe muscle damage for instance. This article explored the effectiveness of levothyroxine sodium tablets (L-T4) replacement therapy in severe complications of hypothyroidism, including treatment dosage, duration of complication recovery, and whether additional treatment is needed. Patient concerns, Diagnoses, and Interventions: We described a case of a 52-year-old woman with HT who exhibited kidney injury, muscle injury, and lipid metabolism disorders. The increased levels of serum creatinine, creatine kinase, cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and the decreased levels of estimated glomerular filtration rate were obviously observed. This patient was started on L-T4 (75 and 100 µg, alternate). Outcomes and Lessons: Following a two-month treatment, the serum creatine kinase level decreased to within normal range. The estimated glomerular filtration rate level was restored, and the serum creatinine level was down-regulated, although slightly higher than the normal range. L-T4 partially reversed HT-induced the disorders of muscle, renal function, and lipid profile of this patient and remarkably alleviated her HT-related symptoms.
- Open Access
- 5 August 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (8) , e9256
Primary hyperaldosteronism associated with type 3 autoimmune polyendocrine syndrome: A rare case report
Key Clinical Message: Primary hyperaldosteronism with type 3 autoimmune polyendocrine syndrome was a rare combination of both hyper‐ and hypoendocrine gland function. Comprehensive treatment including surgery and replacement therapy might be an effective strategy. Primary aldosteronism (PA) is a common cause of secondary hypertension originating from hormones. Type 3 autoimmune polyendocrine syndrome (APS‐3) is characterized by the simultaneous or subsequent occurrence of autoimmune‐mediated endocrine gland damage, except for Addison disease. Here we reported an extremely rare case of a 63‐year‐old woman with PA and APS‐3 who initially presented with hypertension (HT). The APS‐3 of this patient mainly exhibited type 1 diabetes mellitus (T1DM) and Hashimoto's thyroiditis. She underwent the adrenal adenoma resection with a histopathologic diagnosis of adrenal cortical adenoma. After surgery, the HT of this patient was immediately reversed, and the concentration of serum potassium went back to normal. Then, this patient was administered with replacement therapy of insulin and levothyroxine sodium tablets (L‐T4).
- 5 August 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (8) , e9256
Open AccessPrimary hyperaldosteronism associated with type 3 autoimmune polyendocrine syndrome: A rare case report
Key Clinical Message: Primary hyperaldosteronism with type 3 autoimmune polyendocrine syndrome was a rare combination of both hyper‐ and hypoendocrine gland function. Comprehensive treatment including surgery and replacement therapy might be an effective strategy. Primary aldosteronism (PA) is a common cause of secondary hypertension originating from hormones. Type 3 autoimmune polyendocrine syndrome (APS‐3) is characterized by the simultaneous or subsequent occurrence of autoimmune‐mediated endocrine gland damage, except for Addison disease. Here we reported an extremely rare case of a 63‐year‐old woman with PA and APS‐3 who initially presented with hypertension (HT). The APS‐3 of this patient mainly exhibited type 1 diabetes mellitus (T1DM) and Hashimoto's thyroiditis. She underwent the adrenal adenoma resection with a histopathologic diagnosis of adrenal cortical adenoma. After surgery, the HT of this patient was immediately reversed, and the concentration of serum potassium went back to normal. Then, this patient was administered with replacement therapy of insulin and levothyroxine sodium tablets (L‐T4).
- Open Access
- 14 June 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (6) , e9031
Successful management of a multiple endocrine neoplasia type 1‐associated thymic neuroendocrine neoplasms with acute chest pain as initial symptom: A rare case report
Key Clinical Message: Acute chest pain can be the first manifestation of multiple endocrine neoplasia type 1(MEN1)‐associated thymic neuroendocrine neoplasms (NEN). Comprehensive treatment may be an effective strategy for MEN1‐associated NEN. Multiple endocrine neoplasia type 1(MEN1)‐associated thymic neuroendocrine neoplasms (NEN) is caused by the mutation of tumor suppressor MEN1 gene. Patients with MEN1‐associated NEN initially presenting with acute chest pain are very rare. In the manuscript, we reported a case of a 45‐year‐old man who developed MEN1‐associated NEN with acute chest pain as initial symptom. Thoracoscopic thymotomy was performed and thymic NEN was successfully removed. Genetic test showed a germline mutation of MEN1 gene in this patient. Immunohistochemical staining exhibited Syn(+), CgA(+), INSM1(+), CD56(+) and Ki67‐positive cells (2%) in MEN1‐associated NEN. Further evaluation unveiled MEN1‐associated benign tumors including digestive NEN and pituitary gland adenoma. The 99mTc‐HYNIC‐TOC scintigraphy showed that focally increased radioactivity in the mid‐upper abdomen. This patient was administered with 50Gy/25F of radiation dose to treat the postoperative lesions. Subsequently, sandostatin LAR (30 mg per week) was used as systemic therapy. He had no recurrence or metastasis for 6‐month follow‐up. Thus, acute chest pain can be the first manifestation of MEN1‐associated NEN, and comprehensive treatment including surgery, radiation and systemic treatment may be an effective strategy for MEN1‐associated NEN.
- 14 June 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (6) , e9031
Open AccessSuccessful management of a multiple endocrine neoplasia type 1‐associated thymic neuroendocrine neoplasms with acute chest pain as initial symptom: A rare case report
Key Clinical Message: Acute chest pain can be the first manifestation of multiple endocrine neoplasia type 1(MEN1)‐associated thymic neuroendocrine neoplasms (NEN). Comprehensive treatment may be an effective strategy for MEN1‐associated NEN. Multiple endocrine neoplasia type 1(MEN1)‐associated thymic neuroendocrine neoplasms (NEN) is caused by the mutation of tumor suppressor MEN1 gene. Patients with MEN1‐associated NEN initially presenting with acute chest pain are very rare. In the manuscript, we reported a case of a 45‐year‐old man who developed MEN1‐associated NEN with acute chest pain as initial symptom. Thoracoscopic thymotomy was performed and thymic NEN was successfully removed. Genetic test showed a germline mutation of MEN1 gene in this patient. Immunohistochemical staining exhibited Syn(+), CgA(+), INSM1(+), CD56(+) and Ki67‐positive cells (2%) in MEN1‐associated NEN. Further evaluation unveiled MEN1‐associated benign tumors including digestive NEN and pituitary gland adenoma. The 99mTc‐HYNIC‐TOC scintigraphy showed that focally increased radioactivity in the mid‐upper abdomen. This patient was administered with 50Gy/25F of radiation dose to treat the postoperative lesions. Subsequently, sandostatin LAR (30 mg per week) was used as systemic therapy. He had no recurrence or metastasis for 6‐month follow‐up. Thus, acute chest pain can be the first manifestation of MEN1‐associated NEN, and comprehensive treatment including surgery, radiation and systemic treatment may be an effective strategy for MEN1‐associated NEN.